Aug 10 (Reuters) - Heron Therapeutics Inc's
twice-rejected long-acting injection to prevent
chemotherapy-induced nausea and vomiting was finally approved by
the U.S. Food and Drug Administration, marking the biotech's
first regulatory approval.
Read more
No comments:
Post a Comment